Treatment with rituximab in the acute phase of autoimmune TTP, in reports involving 10 or more patients
| Series (year) . | N . | Age (yr), median (range), mean±SD . | %F . | %R . | Number of rituximab infusion, median (range) . | CR (%) . | Days to CR, median (range), mean ± SD . |
|---|---|---|---|---|---|---|---|
| Scully et al (2007)94 | 25 | 43 (17-67) | 76 | 44 | 4 (2-8) | 100 | 11 |
| Jasti et al (2008)90 | 12 | 43 (19-59) | 83 | 8 | (1-13) | 83 | 18 (14-41) |
| Ling et al (2009)91 | 13 | 42 (23-71) | 69 | 54 | NA | 92 | NA |
| de la Rubia et al (2010)92 | 24 | (24-72) | 71 | 42 | 4 (1-8) | 87.5 | 14 (7-35) |
| Scully et al (2011)89 | 40 | 42 (21-76) | 65 | 15 | 4 (2-8) | 82.5 | 12 |
| Froissart et al (2012)82 | 22 | 36.8 ± 11 | 67 | 14 | 4 | 82 | 12 ± 6.7 |
| Page et al (2016)93 | 16 | 41 (20-79) | 75 | 0 | 4 (1-4) | 100 | 21* (5-76) |
| Series (year) . | N . | Age (yr), median (range), mean±SD . | %F . | %R . | Number of rituximab infusion, median (range) . | CR (%) . | Days to CR, median (range), mean ± SD . |
|---|---|---|---|---|---|---|---|
| Scully et al (2007)94 | 25 | 43 (17-67) | 76 | 44 | 4 (2-8) | 100 | 11 |
| Jasti et al (2008)90 | 12 | 43 (19-59) | 83 | 8 | (1-13) | 83 | 18 (14-41) |
| Ling et al (2009)91 | 13 | 42 (23-71) | 69 | 54 | NA | 92 | NA |
| de la Rubia et al (2010)92 | 24 | (24-72) | 71 | 42 | 4 (1-8) | 87.5 | 14 (7-35) |
| Scully et al (2011)89 | 40 | 42 (21-76) | 65 | 15 | 4 (2-8) | 82.5 | 12 |
| Froissart et al (2012)82 | 22 | 36.8 ± 11 | 67 | 14 | 4 | 82 | 12 ± 6.7 |
| Page et al (2016)93 | 16 | 41 (20-79) | 75 | 0 | 4 (1-4) | 100 | 21* (5-76) |
CR, complete remission (durable treatment response at least 30 d after discontinuation of TPE; F, female; N, number of patients; NA, data not available; R, relapsing patients (recurrent disease ≥ 30 d after reaching treatment response); yr, year.
*Days from first to last TPE.